Xarelto Lawsuit News Draws Attention To BMJ Study Noting Possible Twofold Increased Risk Of GI Bleeds

BloodThinnerHelp.com reports on the concerning results of two studies which appear to link anticoagulant Xarelto to an increased risk for the development of dangerous bleeding events among patients. As Xarelto lawsuit filings in Philadelphia and Louisiana continue to mount, and public attention turns to the current multidistrict litigation and mass tort program, many are becoming concerned over the potential severe bleeding side effects which have been connected to the drug through adverse event reports and studies. Plaintiffs who have filed lawsuits in reference to the new-generation blood thinner gain support from these 2015 studies, which seem aligned with their current allegations.

This first notable study conducted in reference to the blood-thinning drug was published in BMJ’s April 2015 issue, and it noted that patients who use Xarelto (rivaroxaban) could be as much as doubling their risk of the likelihood of development of gastrointestinal bleeds when compared with those who take traditional blood-thinning drug warfarin. At the conclusion of their study, the researchers stated, “...we cannot rule out...a more than twofold higher risk of bleeding with rivaroxaban compared with warfarin.”

Another Xarelto-based study published by JAMA Ophthalmology on June 25, 2015 indicated that researchers had discovered a link between the use of rivaroxaban (Xarelto’s generic form) and an elevated risk of the development of eye bleeds called spontaneous vitreous hemorrhage. These researchers stated, “The risk of hemorrhage may be particularly elevated during the transition period when patients are switched from baseline anticoagulant to rivaroxaban therapy and are taking both anticoagulants simultaneously.”

The drug has been given two “black box” warnings from the FDA, which are the most severe product warnings the FDA is able to give before removing a drug completely from the market. In the five years since its 2011 release, Xarelto has become associated with more than 3,400 lawsuits filed across the nation. The complaints have been consolidated to form two main groupings. Over 2,800 Xarelto lawsuits which were federally-filed have been formed into MDL 2592 in Eastern Louisiana, while over 620 other Xarelto lawsuits have been formed into a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.

Attorney Joseph Osborne understands well the potentially devastating and even deadly effects of uncontrollable bleeding events. He is currently working to help other patients who have used Xarelto and who believe that the blood thinner has negatively affected their health. He wants to encourage these individuals to take advantage of the opportunity to investigate their legal rights in full, as they may be entitled to substantial compensation. To better assist those wishing to explore their options further, Attorney Osborne is also currently offering free legal consultations for qualified parties.

To request more Xarelto bleeding lawsuit information, or to ask questions, contact Attorney Joseph Osborne by calling (866) 425-8902.